Eric M Kanza, Amos Nyathirombo, Jemmah P Larbelee, Nicholas O Opoku, Didier K Bakajika, Hayford M Howard, Germain L Mambandu, Maurice M Nigo, Deogratias Ucima Wonyarossi, Françoise Ngave, Kambale Kasonia Kennedy, Kambale Kataliko, Kpehe M Bolay, Simon K Attah, George Olipoh, Sampson Asare, Mupenzi Mumbere, Michel Vaillant, Christine M Halleux, Annette C Kuesel
BACKGROUND: After ivermectin became available, diethylcarbamazine (DEC) use was discontinued because of severe adverse reactions, including ocular reactions, in individuals with high Onchocerca volvulus microfilaridermia (microfilariae/mg skin, SmfD). Assuming long-term ivermectin use led to < 5 SmfD with little or no eye involvement, DEC + ivermectin + albendazole treatment a few months after ivermectin was proposed. In 2018, the US FDA approved moxidectin for treatment of O...
March 15, 2024: Parasites & Vectors